Revolutionizing IgAN Care in the Era of Precision Medicine: Diagnostic Approaches, Evolving Guidelines, and Novel Therapies
Jörg Latus, MD
Jürgen Floege, MD
Michelle O’Shaughnessy, MD, MBBCh
Cracking the Case: A Clinical Consult on Potassium Binders in Patients with Chronic Kidney Disease and Heart Failure
Pam R. Taub, MD, FACC, FASPC
Jan T. Kielstein, MD, FASN, FERA
Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution
Bernhard Hellmich, MD
Andreas Kronbichler, MD
Silke R. Brix, MD, MRCP, SCPR
Pearls of Wisdom: Optimizing Hyperkalemia Management in Patients with CKD
Matthew R. Weir, MD
Nihar Desai, MD
Ellie Kelepouris, MD, FACP, FAHA
No Patient Left Behind! Advancing CKD-Associated Pruritus Care
Kieran McCafferty, MD
Maurizio Gallieni, MD
Breaking the Cycle: Addressing Hyperkalemia in CKD and Heart Failure to Optimize RAASi Therapy
Mikhail Kosiborod, MD
Stephen J. Greene, MD, FACC, FHFSA
Unmasking IgAN: From Suspicion to Timely Diagnosis
Chee Kay Cheung, MBCHB, MRCP, PHD
Advances in IgAN Care From Kidney Week
Sydney Tang, MBBS, MD
Optimizing Outcomes in Patients With IgAN: Novel Therapies and Evolving Guidelines
Jonathan Barratt, PhD
Current Experiences in Identifying and Treating Itch in Patients on Hemodialysis
James Burton, DM, FRCP
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
David Wheeler, MB, CHB, MD, FRCP
Incorporating Targeted Therapies in Treatment Planning for AAV
David Jayne, MD
Achieving Success in IgAN & FSGS
Siân Griffin, MD, PhD
Loreto Gesualdo, MD, FERA
Can We Do Better in IgAN?
Annette Bruchfeld, MD, PhD
Understanding IgAN & FSGS: Pathophysiology and Emerging Therapies
Donald E. Kohan, MD, PhD
Case-Based Management of AAV
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.